Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2015

01-06-2015 | Original Article

Effects of ghrelin on sepsis-induced acute kidney injury: one step forward

Authors: Akef Khowailed, Sandra Mourad Younan, Hend Ashour, Abd Elkarim Kamel, Nivin Sharawy

Published in: Clinical and Experimental Nephrology | Issue 3/2015

Login to get access

Abstract

Background

Among the several disorders induced by sepsis, acute kidney injury (AKI) represents the most important economic burden problem that is associated with high mortality and morbidity rates. The aim of this study was to investigate the anti-inflammatory effects of ghrelin in sepsis-induced AKI and the possible role of vagus nerve.

Methods

Five groups were included: sham, cecal ligation and puncture (CLP), CLP–ghrelin, CLP–vagotomy and CLP–vagotomy–ghrelin group.

Results

Ghrelin treatment immediately after induction of CLP, significantly improved renal Glomerular filtration rate (GFR), serum creatinine, BUN and renal necrosis score as compared to the unprotected CLP group. In addition, ghrelin significantly decreased renal TNF alpha (111.5 ± 10.35 vs. 291.8 ± 15.8 pg/mg ptn), VCAM1 (6.28 ± 1.7 vs. 12.9 ± 1.2 µ/g ptn) and MPO (0.95 ± 0.13 vs. 2.5 ± 0.4 µ/g ptn) without significant increase in renal IL-10. Those effects were abolished by vagotomy.

Conclusion

We concluded that ghrelin could represent new therapeutic window in early treatment of sepsis-induced AKI and this could be mainly due to its anti-inflammatory effects.
Literature
1.
2.
3.
4.
Wu R, et al. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res. 2005;68:318–26.PubMedCrossRef
5.
6.
Wang W, et al. Ghrelin protects mice against endotoxemia-induced acute kidney injury. Am J Physiol Renal Physiol. 2009;297:F1032–7.PubMedCrossRef
7.
8.
Dear JW, et al. Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int. 2006;69:832–6.PubMedCentralPubMedCrossRef
9.
Shetty AK, et al. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods Hum Nutr. 2005;60:109–12.PubMedCrossRef
10.
Leelahavanichkul A, et al. Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol. 2008;295:F1825–35.PubMedCentralPubMedCrossRef
11.
12.
Glauser MP. Sepsis and cytokines. Kansenshogaku Zasshi. 1996;70:1054–61.PubMed
13.
14.
Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol. 1992;262:C854–61.PubMed
15.
Kanno K, et al. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am J Physiol. 1994;267:H2318–24.PubMed
16.
Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediat Inflamm. 2009;2009:137072.
17.
De Vriese AS. Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol. 2003;14:792–805.PubMedCrossRef
18.
Hattori N, et al. GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab. 2001;86:4284–91.PubMedCrossRef
19.
Wu R, et al. Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. Am J Physiol Heart Circ Physiol. 2004;287:H1296–302.PubMedCrossRef
20.
Cunningham PN, et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol. 2002;168:5817–23.PubMedCrossRef
21.
22.
Wang W, et al. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol. 2006;291:F1090–5.PubMedCrossRef
23.
24.
25.
Chorny A, et al. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol. 2008;180:8369–77.PubMedCrossRef
26.
Wang H, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–8.PubMedCrossRef
27.
Rosas-Ballina M, et al. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci USA. 2008;105:11008–13.PubMedCentralPubMedCrossRef
28.
Yeboah MM, et al. Nicotinic acetylcholine receptor expression and regulation in the rat kidney after ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2008;295:F654–F661.PubMedCentralPubMedCrossRef
29.
Borovikova LV, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–62.PubMedCrossRef
30.
31.
Heider TR, et al. Acute vagotomy does not augment the systemic inflammatory response in patients with peptic ulcer disease. Am Surg. 2004;70:342–6.PubMed
32.
Kellum JA, Ronco C, Vincent J-L (eds): Controversies in Acute Kidney Injury. Contrib Nephrol. Basel, Karger, 2011; 174 p. 89–97.
33.
Olguner CG, et al. Ischemic preconditioning attenuates lipid peroxidation and apoptosis in the cecal ligation and puncture model of sepsis. Exp Ther Med. 2013;5:1581–8.PubMedCentralPubMed
Metadata
Title
Effects of ghrelin on sepsis-induced acute kidney injury: one step forward
Authors
Akef Khowailed
Sandra Mourad Younan
Hend Ashour
Abd Elkarim Kamel
Nivin Sharawy
Publication date
01-06-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-1006-x

Other articles of this Issue 3/2015

Clinical and Experimental Nephrology 3/2015 Go to the issue

Original Article

Underestimating chronic kidney disease by urine dipstick without serum creatinine as a screening tool in the general Japanese population

Original Article

Efficacy and safety of fluoroscopic manipulation using the alpha-replacer for peritoneal catheter malposition

Original Article

Glomerular basement membrane injuries in IgA nephropathy evaluated by double immunostaining for α5(IV) and α2(IV) chains of type IV collagen and low-vacuum scanning electron microscopy

Original Article

The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients

Original Article

Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study

Original Article

The incidence, risk factors, and outcomes of acute kidney injury in patients with pyogenic liver abscesses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits